research Hand-Foot and Stump Syndrome to Sorafenib
Sorafenib may cause hand-foot and stump syndrome, requiring early detection and management.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
research Sorafenib-induced eruption resembling pityriasis rubra pilaris
A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.
research Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
Sorafenib after liver surgery may increase survival for some liver cancer patients.
research Sorafenib-Associated Facial Acneiform Eruption
Sorafenib can cause facial acne-like eruptions, which improve after reducing the dose or stopping the drug.
research Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment
Photodynamic therapy improved skin issues from sorafenib when other treatments failed.
research A distinct cutaneous reaction to sorafenib and a multikinase inhibitor
Sorafenib can cause a unique skin reaction.
research Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
research Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib
Sorafenib often causes skin side effects, indicating effective cancer treatment.
research Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.
research Sorafenib stimulates human skin type mast cell degranulation and maturation
Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.
research Delayed onset perforating folliculitis associated with sorafenib
Sorafenib can cause delayed skin problems, so patients need careful monitoring.
research Case of alopecia induced by sorafenib, possible mechanism similar to alopecia areata
Sorafenib may cause hair loss in a way similar to alopecia areata.
research Sorafenib-Induced Pityriasis Rubra Pilaris-like Eruption: A Case Report
Sorafenib can cause rare skin reactions, but treatment can continue with additional care.
research Synergistic effect of sorafenib with Platycladus orientalis (L) leaf extract on cervical cancer
Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.
research Sorafenib-induced Facial Acneiform Eruption
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
research Transient perforating folliculitis induced by sorafenib
Sorafenib can cause a temporary skin condition that goes away after stopping the drug.
research Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Skin toxicity of anti‐cancer therapy
Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
research Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female
A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
research Adverse Hair Reactions to New Targeted Therapies for Cancer
New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
research Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
research Tombo em João Pessoa dá força a Memorial da Arquitetura Paraibana
Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.
research Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.
research BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
research Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.